| dc.creator | Zapata Cardona, María Isabel | |
| dc.creator | Flórez Álvarez, Lizdany | |
| dc.creator | Guerra Sandoval, Ariadna Lucia | |
| dc.creator | Medina Chvatal, Mateo | |
| dc.creator | Guerra Almonacid, Carlos Martín | |
| dc.creator | Hincapié García, Jaime Alejandro | |
| dc.creator | Hernández López, Juan Carlos | |
| dc.creator | Rugeles López, María Teresa | |
| dc.creator | Zapata Builes, Wildeman | |
| dc.date | 2023-06-13T18:47:09Z | |
| dc.date | 2023-06-13T18:47:09Z | |
| dc.date | 2023 | |
| dc.date.accessioned | 2024-04-23T18:12:25Z | |
| dc.date.available | 2024-04-23T18:12:25Z | |
| dc.identifier | Zapata-Cardona MI, Florez-Alvarez L, Guerra-Sandoval AL, Chvatal-Medina M, Guerra-Almonacid CM, Hincapie-Garcia J, Hernandez JC, Rugeles MT, Zapata-Builes W. In vitro and in silico evaluation of antiretrovirals against SARS-CoV-2: A drug repurposing approach. AIMS Microbiol. 2023 Jan 16;9(1):20-40. doi: 10.3934/microbiol.2023002. PMID: 36891537; PMCID: PMC9988408. | |
| dc.identifier | 2471-1888 | |
| dc.identifier | https://hdl.handle.net/10495/35476 | |
| dc.identifier | 10.3934/microbiol.2023002 | |
| dc.identifier | 2471-1888 | |
| dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/9230529 | |
| dc.description | Abstract: Background: Drug repurposing is a valuable strategy for rapidly developing drugs for
treating COVID-19. This study aimed to evaluate the antiviral effect of six antiretrovirals against
SARS-CoV-2 in vitro and in silico. Methods: The cytotoxicity of lamivudine, emtricitabine, tenofovir,
abacavir, efavirenz and raltegravir on Vero E6 was evaluated by MTT assay. The antiviral activity of
each of these compounds was evaluated via a pre-post treatment strategy. The reduction in the viral
titer was assessed by plaque assay. In addition, the affinities of the antiretroviral interaction with viral
targets RdRp (RNA-dependent RNA polymerase), ExoN-NSP10 (exoribonuclease and its cofactor,
the non-structural protein 10) complex and 3CLpro (3-chymotrypsin-like cysteine protease) were
evaluated by molecular docking. Results: Lamivudine exhibited antiviral activity against SARS-CoV-2
at 200 µM (58.3%) and 100 µM (66.7%), while emtricitabine showed anti-SARS-CoV-2 activity
at 100 µM (59.6%), 50 µM (43.4%) and 25 µM (33.3%). Raltegravir inhibited SARS-CoV-2 at 25, 12.5
and 6.3 µM (43.3%, 39.9% and 38.2%, respectively). The interaction between the antiretrovirals and
SARS-CoV-2 RdRp, ExoN-NSP10 and 3CLpro yielded favorable binding energies (from −4.9
kcal/mol to −7.7 kcal/mol) using bioinformatics methods. Conclusion: Lamivudine, emtricitabine and
raltegravir showed in vitro antiviral effects against the D614G strain of SARS-CoV-2. Raltegravir was
the compound with the greatest in vitro antiviral potential at low concentrations, and it showed the
highest binding affinities with crucial SARS-CoV-2 proteins during the viral replication cycle.
However, further studies on the therapeutic utility of raltegravir in patients with COVID-19 are
required | |
| dc.description | COL0012444 | |
| dc.description | COL0074661 | |
| dc.format | 21 | |
| dc.format | application/pdf | |
| dc.format | application/pdf | |
| dc.language | eng | |
| dc.publisher | AIMS Press | |
| dc.publisher | Inmunovirología | |
| dc.publisher | Promoción y Prevención Farmacéutica | |
| dc.publisher | Springfield, Estados Unidos | |
| dc.relation | AIMS Microbiol. | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.rights | http://creativecommons.org/licenses/by/2.5/co/ | |
| dc.rights | http://purl.org/coar/access_right/c_abf2 | |
| dc.rights | https://creativecommons.org/licenses/by/4.0/ | |
| dc.subject | SARS-CoV-2 | |
| dc.subject | Antirretrovirales | |
| dc.subject | Anti-Retroviral Agents | |
| dc.subject | Tratamiento Farmacológico de COVID-19 | |
| dc.subject | COVID-19 Drug Treatment | |
| dc.subject | Simulación del Acoplamiento Molecular | |
| dc.subject | Molecular Docking Simulation | |
| dc.subject | Reposicionamiento de Medicamentos | |
| dc.subject | Drug Repositioning | |
| dc.subject | Enfermedades Transmisibles | |
| dc.subject | Communicable Diseases | |
| dc.title | In vitro and in silico evaluation of antiretrovirals against SARS-CoV-2: A drug repurposing approach | |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:eu-repo/semantics/publishedVersion | |
| dc.type | http://purl.org/coar/resource_type/c_2df8fbb1 | |
| dc.type | https://purl.org/redcol/resource_type/ART | |
| dc.type | Artículo de investigación | |
